Shukra Pharmaceuticals Lists on NSE, Enhancing Liquidity and Investor Access
Shukra Pharmaceuticals Limited shares listed on NSE on August 14, 2026. The dual listing on NSE and BSE aims to boost liquidity and expand the investor base. The reference price on NSE was set by BSE's closing price on August 13, 2026.
The dual listing is expected to improve liquidity and investor base, which can positively impact the company's valuation and market presence.
The listing on a major stock exchange like NSE is a positive development for the company, indicating growth and increased accessibility for investors.
Shukra Pharmaceuticals Limited announced that its equity shares have been listed and admitted to dealings on the Main Board of the National Stock Exchange of India Limited (NSE) effective Friday, 14th August 2026.
The company's equity shares will continue to be traded on the BSE Limited (BSE). The base reference price on the NSE for the trading session on August 14, 2026, was determined based on the closing market price of the shares on the BSE on August 13, 2026.
This dual listing on both NSE and BSE is a significant milestone intended to enhance liquidity, broaden the investor base, and maximize stakeholder value.
What to do with a filing like this
Shukra Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shukra Pharmaceuticals Limited. Read the original for the full detail.